

	2
B. Background	2
C. Definitions.....	2
D. Policy	2
E. Conditions of Coverage	4
F. Related Policies/Rules	4
G. Review/Revision History	4
H. References	4



11. Clinical Utility Evaluation: *MTHFR* Genetic Testin

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.



28. *MolDx: Genetic Testing for Hypercoagulability/Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)*. Medicare Coverage Database; 2015. LCD ID L35984. Revised July 20, 2023. Accessed March 14, 2024. www.cms.gov
29. *MolDx: Molecular Diagnostic Tests (MDT)*. Medicare Coverage Database; 2017. LCD ID L36807. Revised April 27, 2023. Accessed March 14, 2024. www.cms.gov
30. *MolDx: Pharmacogenomics Testing*. Medicare Coverage Database; 2020. LCD ID L38435. Updated August 24, 2023. Accessed March 14, 2024. www.cms.gov
31. *MolDx: Repeat Germline Testing*. Medicare Coverage Database; 2020. LCD ID L38429. Revised January 23, 2024. Accessed March 14, 2024. www.cms.gov
32. *Molecular Test Assessment: GeneSight Psychotropic (Assurex Health Inc./Myriad Neuroscience)*. Hayes; 2021. Updated November 13, 2023. Accessed March 14, 2024. www.evidence.hayesinc.com
33. National Cancer Institute (NCI). NCI Dictionary of Genetics Terms. National Institute of Health. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738837/>

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.